文献速递慢性肾脏病血液净化与透析

鸟苷酸环化酶C激动剂利那洛肽改善腺嘌呤诱导慢性肾脏病小鼠的肠-心-肾轴

The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

本研究在腺嘌呤诱导的肾衰竭小鼠模型中,给予鸟苷酸环化酶C激动剂利那洛肽,通过代谢组学和宏基因组学方法分析肾功能、肠源性尿毒症毒素及肠道菌群变化。结果显示,利那洛肽在临床低剂量10 μg/kg下降低血浆TMAO水平,高剂量100 μg/kg下改善肾功能并减少多种尿毒症毒素,同时减轻肾脏炎症和纤维化及心脏纤维化,修复肠道屏障,提示其可能通过调节肠-心-肾轴预防心肾综合征。

要点

  • 利那洛肽在腺嘌呤诱导的肾衰竭小鼠中降低血浆TMAO水平。
  • 高剂量利那洛肽改善肾功能并减少尿毒症毒素。
  • 利那洛肽减轻肾脏和心脏纤维化,修复肠道屏障。

核心结论

  • 利那洛肽降低TMAO和尿毒症毒素水平,可能通过调节肠-心-肾轴成为防治心肾综合征的有力工具。

研究设计与样本

  • 研究采用腺嘌呤诱导的肾衰竭小鼠模型,给予利那洛肽,并分析肾功能、肠源性尿毒症毒素及肠道菌群。

主要发现

  • 利那洛肽在临床低剂量10 μg/kg下降低血浆TMAO水平,高剂量100 μg/kg下改善肾功能并减少多种尿毒症毒素。
  • 利那洛肽减轻肾脏炎症和纤维化及心脏纤维化,降低胶原I、TGF-β、Gal-3和ST2基因表达,并减少血浆Gal-3和ST2水平。
  • 利那洛肽减少小肠隐窝F4/80阳性巨噬细胞,恢复结肠claudin-1水平,改善“漏肠”。
  • 宏基因组分析提示梭菌目可能负责TMAO水平的变化。
  • 在胆碱喂养的促动脉粥样硬化模型中,利那洛肽也降低TMAO水平。

临床怎么用

  • 利那洛肽可能作为调节肠-心-肾轴、降低TMAO和尿毒症毒素的潜在治疗药物,用于心肾综合征的防治。

局限性

  • 研究为小鼠模型,结果需在临床研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiorenal syndrome is a major cause of mortality in patients with chronic kidney disease (CKD). However, the involvement of detrimental humoral mediators in the pathogenesis of cardiorenal syndrome is still controversial. Trimethylamine-N-oxide (TMAO), a hepatic metabolic product of trimethylamine generated from dietary phosphatidylcholine or carnitine derived by the gut microbiota, has been linked directly with progression of cardiovascular disease and renal dysfunction. Thus, targeting TMAO may be a novel strategy for the prevention of cardiovascular disease and chronic kidney disease. METHODS: Linaclotide, a guanylate cyclase C agonist, was administered to adenine-induced renal failure (RF) mice and changes in renal function and levels of gut-derived uremic toxins, as well as the gut microbiota community, were analyzed using metabolomic and metagenomic methods to reveal its cardiorenal effect. RESULTS: Linaclotide decreased the plasma levels of TMAO at a clinically used low dose of 10 μg/kg in the adenine-induced RF mouse model. At a high concentration of 100 μg/kg, linaclotide clearly improved renal function and reduced the levels of various uremic toxins. A reduction in TMAO levels following linaclotide treatment was also observed in a choline-fed pro-atherosclerotic model. Linaclotide ameliorated renal inflammation and fibrosis and cardiac fibrosis, as well as decreased the expression of collagen I, transforming growth factor-β, galectin-3 (Gal-3) and ST2 genes. Plasma levels of Gal-3 and ST2 were also reduced. Because exposure of cardiomyocytes to TMAO increased fibronectin expression, these data suggest that linaclotide reduced the levels of TMAO and various uremic toxins and may result in not only renal, but also cardiac, fibrosis. F4/80-positive macrophages were abundant in small intestinal crypts in RF mice, and this increased expression was decreased by linaclotide. Reduced colonic claudin-1 levels were also restored by linaclotide, suggesting that linaclotide ameliorated the 'leaky gut' in RF mice. Metagenomic analysis revealed that the microbial order Clostridiales could be responsible for the change in TMAO levels. CONCLUSION: Linaclotide reduced TMAO and uremic toxin levels and could be a powerful tool for the prevention and control of the cardiorenal syndrome by modification of the gut-cardio-renal axis.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Nanto-Hara F, Kanemitsu Y, Fukuda S, et al. The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease. Nephrol Dial Transplant. 2020. PMID: 31411705. doi:10.1093/ndt/gfz126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。